PTD-DBM stands for Protein Transduction Domain-fused Dishevelled Binding Motif. It is a synthetic peptide developed in Professor Kang-Yell Choi's laboratory at Yonsei University, South Korea, and first described in research published between 2015 and 2017. The peptide has a molecular weight of 3080.7 g/mol and molecular formula C₁₂₄H₂₂₃N₆₁O₂₈S₂.

The name describes its two functional components, which serve different purposes in the molecule:

PTD-DBM is water-soluble and compatible with an aqueous glycol-free carrier. No DMSO is required for formulation or for intracellular delivery; the PTD sequence handles membrane penetration independently. This distinguishes it from some competing approaches that rely on DMSO as a penetration vehicle.

The Wnt/beta-catenin signalling pathway is one of the most studied pathways in developmental biology. It governs cell proliferation, differentiation, and tissue maintenance across many organ systems. In hair follicles specifically, it is critical: Wnt signalling is required for follicle development in the embryo, for the activation of follicle stem cells at the onset of anagen, and for sustaining the growth phase once underway. Reduced Wnt/beta-catenin activity is associated with follicle miniaturisation and the transition from terminal to vellus hair characteristic of androgenetic alopecia. The pathway is covered in full in the Wnt/beta-catenin pathway and hair.

CXXC5 is a zinc finger protein that functions as a negative regulator of this pathway. Its mode of action is to bind to Dishevelled, a key scaffolding protein in the Wnt signalling cascade. When CXXC5 occupies Dvl, it suppresses downstream beta-catenin accumulation and the gene expression changes that Wnt signalling drives. In effect, CXXC5 is a brake on the pathway: it is induced by active Wnt signalling and then dampens that signalling in a negative feedback loop. CXXC5 itself is covered in more depth in what is CXXC5 and why does it matter for hair loss.

The 2017 research from Yonsei University established that CXXC5 is upregulated in miniaturised hair follicles and arrector pili muscles in human balding scalps. Research from the same group also indicates that DHT, the androgen central to the mechanism of androgenetic alopecia, upregulates CXXC5 expression in dermal papilla cells, providing a mechanistic link between androgen signalling and suppression of the Wnt pathway. For more on how DHT drives follicle miniaturisation, the article on DHT and the follicle covers this pathway in full.

Once PTD-DBM crosses the cell membrane via its PTD component, the DBM domain presents a sequence that mimics the CXXC5 binding motif for Dvl. This allows PTD-DBM to compete with endogenous CXXC5 for the Dvl binding site. When PTD-DBM occupies that site, CXXC5 cannot attach. The negative feedback loop is disrupted: CXXC5 cannot suppress Dvl's role in the downstream signalling cascade, and Wnt/beta-catenin pathway activity is restored.

The distinction between this mechanism and simply "activating Wnt" with an exogenous ligand is worth noting. PTD-DBM does not add a Wnt signal; it removes a specific inhibitor of the signal the follicle already generates. The aim is to restore a suppressed pathway to closer-to-normal activity, not to drive the pathway above its natural operating range.

The research base for PTD-DBM rests on two foundational papers from the Choi laboratory at Yonsei University. Neither involves completed human clinical trials. The evidence is mechanistic and animal-model based, with in vitro data on human cells providing supporting context.

The mouse research applied PTD-DBM at 10 mM, equivalent to approximately 3% w/v. At current raw material pricing, 3% in a 50ml bottle would require approximately 1.5g of PTD-DBM, which is commercially impossible by a wide margin. This is a translation problem that affects all high-MW peptides in topical application: mouse studies apply saturating doses that are not designed to be commercially formulated.

The in vitro data from the 2015 JEM paper, however, tested PTD-DBM at 2 µM and 10 µM in cell culture and found statistically significant effects at both concentrations. Converting AmpleLab's 0.01% formulation to molar terms provides a useful reference point:

The rationale for 0.01% is that it provides meaningful headroom above the concentrations shown to be active in vitro, while remaining formulation-viable. In vitro concentrations are measured in free solution with no skin barrier. A topical serum must cross the stratum corneum, penetrate follicular structures, and reach dermal papilla cells before any fraction can engage the intracellular target. The formulation is designed to address some of these delivery challenges through the PTD domain and the inclusion of Methyl Vanillate. But some penetration loss is simply inherent to topical delivery of a peptide of this molecular weight. Starting at 32.4 µM rather than 3.24 µM provides a more defensible safety margin against that loss.

AmpleLab discloses this concentration (0.01%) on the label. It appears last in the INCI list; at 0.01%, this is the correct position under INCI descending order rules; there is no more transparent way to represent it. What sets the AmpleLab approach apart is that the concentration is stated rather than left to inference.

Methyl Vanillate is the methyl ester of vanillic acid, a naturally derived compound from vanillin. It is included in this formula at 0.2% in the role of a cosmetic penetration enhancer: it has been investigated for its ability to facilitate permeation of actives through the outer layers of the skin, with inclusion here intended to support delivery of PTD-DBM toward the follicular structures it is intended to reach.

PTD-DBM already carries its own intracellular delivery mechanism in the PTD domain, which handles membrane penetration once the peptide reaches the cell surface. Methyl Vanillate operates at an earlier stage: the transit from skin surface to follicle. The two mechanisms are complementary. Methyl Vanillate has been investigated both for penetration-supporting properties and for potential biological effects relevant to Wnt signalling; both considerations are relevant to its inclusion in this formula.

Methyl Vanillate appears in at least one other commercial PTD-DBM formula as well; its inclusion here is an independent formulation decision based on its established function as a cosmetic penetration enhancer, not a derivative of competitor formulation choices.

The formula contains no glycols, no DMSO, and no compounds with systemic penetration enhancement properties that would raise safety or regulatory concerns. It is the same glycol-free aqueous carrier architecture used across the AmpleLab range, adapted for the specific requirements of this active. An article on how to read INCI lists and what ingredient position tells you about concentration is available here: why INCI order tells you more than the ingredients list.

The most established commercial PTD-DBM product on the market today is US-only, available at $69.95 for 25ml, distributed through their website and a healthcare practitioner network. Their concentration is not disclosed on the label. When asked directly, their customer support team confirmed it in writing: 0.001%.

At least one other US-based brand also produces a PTD-DBM serum: aqueous, no DMSO, and positioned in a similar market segment. Their concentration is not publicly disclosed. Without a stated figure, meaningful comparison is not possible, though the absence of disclosure is itself a data point for buyers evaluating what formulation transparency looks like in this category.

The DMSO point is a genuine formulation difference, not a marketing claim. DMSO is a pharmaceutical and research solvent with unusually strong penetration-enhancing properties and a characteristic odour profile. It is commonly used as a vehicle in pharmaceutical and research applications. PTD-DBM does not require it: the PTD component of the molecule is designed to facilitate cellular uptake without relying on DMSO. AmpleLab's formula demonstrates this with a clean aqueous carrier and no DMSO.

The more practical concern for users with established protocols is that DMSO is not selective. It enhances the penetration of whatever else is present on the skin at the time of application, not just the intended active. For someone applying PTD-DBM alongside minoxidil, topical finasteride or dutasteride, copper peptides, or other scalp actives, DMSO could drive co-applied substances through the skin barrier at higher rates than those compounds were formulated or tested to deliver. The implications for systemic absorption of co-applied treatments are not well-characterised in a topical PTD-DBM context. For users with layered protocols, this is a practical variable a DMSO-free formulation removes entirely.

For UK buyers, this US competitor is functionally inaccessible: US-only fulfilment, international shipping costs, customs and import duty at the UK border, and a minimum 2-week lead time. AmpleLab's 50ml bottle ships from within the UK, with no import complications, at £99.99, and contains 20 times more PTD-DBM per bottle.

Community discussions around Wnt pathway hair compounds frequently conflate PTD-DBM with JXL069 and PP405. These are entirely different molecules with a different primary mechanism and entirely separate research lineage. Clarifying the distinction is worth doing because the conflation affects how people evaluate both categories.

JXL069 and PP405 are both mitochondrial pyruvate carrier (MPC) inhibitors developed from research at UCLA. Their mechanism is metabolic: MPC inhibition blocks pyruvate entry into the mitochondria, shifts cellular metabolism toward glycolysis, drives lactate accumulation, upregulates lactate dehydrogenase (LDH), and activates dormant hair follicle stem cells through this metabolic signal, promoting anagen entry. Some secondary sources describe these compounds as Wnt pathway activators, but this is inaccurate as a primary mechanism description. Any Wnt involvement in PP405's effects is downstream of the metabolic shift, not the primary mode of action per Pelage Pharmaceuticals' own published data.

JXL069 and PP405 are also not the same compound. They are related molecules from the same UCLA research programme, but Pelage has confirmed they are distinct. Vendors marketing JXL069 as PP405 are factually incorrect. PP405 was specifically engineered to degrade before reaching systemic circulation; JXL069 was not, and carries a risk of lactic acidosis if it enters systemic circulation. The two safety profiles are not interchangeable.

PP405 Phase 2a data (published 2025) showed 31% of male patients with higher-degree hair loss achieving more than 20% hair density increase at 8 weeks versus 0% in the placebo group. Phase 3 is planned for 2026; commercial availability is estimated 2027–2028. AmpleLab does not make or sell any PP405 or JXL069 product and makes no claims in relation to those compounds.

AmpleLab's PTD-DBM Hair and Scalp Serum is a cosmetic formulation. It is not a medicine and is not intended to diagnose, treat, cure, or prevent any condition. The research referenced in this article is provided for educational purposes. No clinical hair regrowth claims are made. For any concerns about hair loss, consult a qualified healthcare professional.

AmpleLab.